Spironolactone reduced systolic BP by 15.6 mmHg (P=0.005), PIIINP by 0.6 microg/L (P=0.04), and pulse wave velocity by 0.6 m/s (P=0.008) compared with placebo in hypertensive type II diabetics.
RCT (n=10)
Double-blind
Crossover
Does spironolactone reduce blood pressure, PIIINP, and pulse wave velocity in hypertensive type II diabetics?
Spironolactone effectively reduces systolic blood pressure, arterial stiffness, and markers of collagen turnover in hypertensive patients with type II diabetes.
Effect estimate: Reduction of 15.6 mmHg (95% CI 2.7-28.5)
p-value: p=0.005
AIMS: To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics. METHODS: Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase. RESULTS: Compared with placebo, spironolactone reduced systolic BP by 15.6 +/- 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 +/- 0.3 microg l(-1) (P = 0.04, 95% CI 0.02-1.1 microg l(-1)) and PWV by 0.6 +/- 0.2 m s(-1) (P = 0.008, 95% CI 0.18-1.02 m s(-1)). CONCLUSIONS: Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.
Davies et al. (Wed,) conducted a rct in Type II diabetes and hypertension (n=10). Spironolactone vs. Placebo was evaluated on Systolic BP (Reduction of 15.6 mmHg, 95% CI 2.7-28.5, p=0.005). Spironolactone reduced systolic BP by 15.6 mmHg (P=0.005), PIIINP by 0.6 microg/L (P=0.04), and pulse wave velocity by 0.6 m/s (P=0.008) compared with placebo in hypertensive type II diabetics.